Tesa 10 peptide is a 10 mg vial of tesamorelin, a synthetic GHRH analog. Learn how it works, how it is reconstituted, typical research dosing, and safety.
Tesa 10 peptide is a 10 mg vial of tesamorelin, a synthetic growth hormone–releasing hormone (GHRH) analog. The “10” describes the amount of lyophilized peptide powder in the vial, not a separate molecule, so tesa 10 and tesamorelin 10 mg refer to the same compound. It is studied for its ability to stimulate the body’s own growth hormone release, and as the prescription drug Egrifta it is FDA-approved for a specific group of patients with HIV-associated lipodystrophy.
What Is Tesa 10 Peptide?
Tesamorelin is a 44-amino-acid peptide modeled on natural GHRH, with a small chemical modification that helps it resist rapid enzymatic breakdown. It binds GHRH receptors on the pituitary gland and triggers growth hormone release in the body’s normal pulsatile pattern.
The FDA approved tesamorelin in 2010 as Egrifta for reducing excess visceral abdominal fat in HIV-positive adults with lipodystrophy, and a lower-dose version, Egrifta SV, followed in 2019. That approval is narrow. Tesamorelin is not FDA-approved for general weight loss, athletic performance, or anti-aging use.
In the research-peptide market, tesa peptide is sold as a lyophilized (freeze-dried) powder in 2 mg, 5 mg, and 10 mg vials. The 10 mg size is popular because it costs less per milligram and reduces how often a researcher has to reorder.
How Tesamorelin Works in the Body
Tesamorelin does not deliver growth hormone directly. Instead, it signals the pituitary to release the hormone, which then prompts the liver to produce IGF-1, the mediator behind many downstream effects.
- Mechanism: GHRH receptor agonist on pituitary somatotroph cells.
- Effect: Increased pulsatile growth hormone release and a rise in serum IGF-1.
- Half-life: Roughly 26–38 minutes in blood, which is why daily subcutaneous dosing is standard.
- Research focus: Visceral adipose tissue reduction, lipid metabolism, and body composition.
Because the drug works upstream of growth hormone production, it depends on a functioning pituitary. Someone with pituitary damage or disease would not respond the same way, which is one reason tesamorelin is a prescription product rather than a supplement.
Tesa 10 Peptide Reconstitution and Dosing
Lyophilized tesamorelin must be mixed with bacteriostatic water before use. A common setup pairs a 10 mg vial with a bacteriostatic water 10 ml bottle, which supplies enough diluent for several vials when stored properly.
Adding more water makes small doses easier to measure accurately. Adding less water keeps the injection volume low. The table below shows how the math works out.
| Diluent added to a 10 mg vial | Concentration | Volume for a 1 mg dose |
|---|---|---|
| 1 mL | 10 mg/mL | 0.10 mL |
| 2 mL | 5 mg/mL | 0.20 mL |
| 2.5 mL | 4 mg/mL | 0.25 mL |
| 5 mL | 2 mg/mL | 0.50 mL |
Swirl the vial gently; do not shake it, because vigorous agitation can damage the peptide. Store the reconstituted solution in a refrigerator and avoid repeated temperature swings.
The FDA label for Egrifta calls for 2 mg injected once daily, while Egrifta SV uses 1.4 mg daily. Research protocols commonly describe 1 mg to 2 mg per day, sometimes split into two injections. Timing tends to follow natural growth hormone rhythms, with evening dosing being the most discussed option. A similar conversation surrounds when to take aod 9604 peptide, another fat-metabolism research compound that is often compared with GHRH analogs.
Tesamorelin is a prescription drug in the United States, and self-dosing with research-grade powder carries real risks. Anyone considering it should speak with a licensed healthcare professional first.
How Tesa 10 Compares With Other Growth Hormone Peptides
Several peptides act on the growth hormone axis, but they are not interchangeable. The table below summarizes the most common comparisons researchers make.
| Peptide | Primary mechanism | Approximate half-life | Typical research dose |
|---|---|---|---|
| Tesamorelin (tesa 10) | GHRH receptor agonist | 26–38 minutes | 1–2 mg/day |
| Sermorelin | GHRH receptor agonist | ~10–20 minutes | 200–500 mcg/day |
| Mod GRF 1-29 (CJC-1295 no DAC) | GHRH receptor agonist | ~30 minutes | 100 mcg, 1–3x/day |
| Ipamorelin | Ghrelin receptor agonist (GHRP) | ~2 hours | 100–300 mcg, 1–3x/day |
The key distinction is that GHRH analogs and ghrelin-receptor agonists act on different receptors, which is why some research designs combine them for a larger growth hormone pulse. Tesamorelin occupies the GHRH side of that pairing.
Side Effects and Safety Considerations
In clinical trials, the most frequently reported side effects were injection site reactions, joint pain, and swelling of the hands and feet. Carpal tunnel–like symptoms, muscle pain, and elevated IGF-1 levels also appeared in study data.
- Pregnancy and active malignancy are contraindications on the FDA label.
- Because the drug raises IGF-1, monitoring is part of clinical use.
- Blood glucose changes are possible, so people with diabetes need medical supervision.
- Tesamorelin is banned by the World Anti-Doping Agency for athletes in competition.
Tesamorelin is not FDA-approved for general weight loss, and no research peptide should be treated as a substitute for medical care.
Sourcing, Legality, and Quality Checks
Tesamorelin is a prescription drug in the United States, so selling it as a research chemical does not make it legal for human use. Buyers who research where to buy bpc-157 peptide should apply the same standards here: a third-party certificate of analysis, HPLC purity data, mass spectrometry confirmation, and endotoxin testing.
Price is a poor quality signal, and a vendor that publishes no testing documentation is a red flag. Good documentation matters because underdosed or impure powder can cause unexpected reactions.
Analytical certificates should list a purity figure, a testing method, and a lot number that matches the vial label.
Key Takeaways
- Tesa 10 peptide is a 10 mg vial of tesamorelin, a synthetic GHRH analog.
- Tesamorelin is FDA-approved as Egrifta for visceral fat in HIV-associated lipodystrophy, not for general weight loss.
- Typical clinical dosing is 1.4 mg to 2 mg daily by subcutaneous injection.
- A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a 5 mg/mL solution.
- Reconstituted peptide should be refrigerated and handled gently.
Frequently Asked Questions
Is tesa 10 peptide the same as tesamorelin?
Yes. Tesa 10 peptide is simply a 10 mg vial of tesamorelin, the same synthetic GHRH analog sold under the prescription brand name Egrifta. The number refers to the amount of lyophilized powder in the vial, not to a different formulation or a stronger version of the peptide.
How much bacteriostatic water should I add to a 10 mg tesa vial?
There is no single correct volume, but 2 mL is a common choice because it produces a 5 mg/mL solution, where 0.2 mL equals 1 mg. Adding 5 mL instead gives a 2 mg/mL solution that is easier to measure in small increments. Use only bacteriostatic water intended for peptide reconstitution, and refrigerate the mixed vial.
Is tesa 10 peptide legal in the United States?
Tesamorelin is a prescription drug in the US, so buying it without a prescription is not legal, even when a vendor labels it for research use only. Research-grade vials sold online are not FDA-approved and are not quality-controlled the way prescription Egrifta is. Talk with a licensed healthcare professional before using any injectable peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.